Merus (NASDAQ:MRUS) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Merus (NASDAQ:MRUS) in a research report released on Monday,Benzinga reports. HC Wainwright currently has a $85.00 price target on the biotechnology company’s stock.

MRUS has been the subject of several other research reports. Piper Sandler initiated coverage on Merus in a research note on Thursday, February 13th. They set an “overweight” rating and a $84.00 price target for the company. Needham & Company LLC dropped their price target on Merus from $85.00 to $83.00 and set a “buy” rating for the company in a research note on Friday. The Goldman Sachs Group initiated coverage on Merus in a research note on Thursday, November 21st. They set a “buy” rating and a $73.00 price target for the company. Guggenheim reaffirmed a “buy” rating on shares of Merus in a research note on Wednesday, February 12th. Finally, Wells Fargo & Company initiated coverage on Merus in a research note on Friday, February 7th. They set an “overweight” rating and a $91.00 price target for the company. One equities research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Merus presently has an average rating of “Buy” and a consensus price target of $85.77.

Merus Stock Performance

NASDAQ:MRUS opened at $45.47 on Monday. The firm has a market capitalization of $3.11 billion, a price-to-earnings ratio of -11.51 and a beta of 1.11. Merus has a 52-week low of $37.77 and a 52-week high of $61.61. The stock has a fifty day moving average of $42.04 and a 200 day moving average of $46.74.

Merus (NASDAQ:MRUS) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The company had revenue of $9.14 million during the quarter, compared to analyst estimates of $10.57 million. Equities analysts forecast that Merus will post -3.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN increased its holdings in Merus by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 300 shares during the period. Parkman Healthcare Partners LLC increased its holdings in Merus by 0.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 45,680 shares of the biotechnology company’s stock valued at $1,921,000 after purchasing an additional 331 shares during the period. Deutsche Bank AG increased its holdings in Merus by 0.4% during the 4th quarter. Deutsche Bank AG now owns 113,056 shares of the biotechnology company’s stock valued at $4,754,000 after purchasing an additional 416 shares during the period. Gordian Capital Singapore Pte Ltd increased its holdings in Merus by 10.4% during the 3rd quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company’s stock valued at $250,000 after purchasing an additional 470 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Merus by 24.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 489 shares during the period. Hedge funds and other institutional investors own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.